Compounded oral, sublingual & ODT GLP-1 programs

ODT (orally disintegrating tablet) programs

Captured ODT programs. ODT, sublingual, and swallowed-oral products are different formulations and are never merged into one ranking.

Sublingual programs

Captured sublingual programs. Sublingual absorption is formulation-specific and uncharacterized for compounded products.

Oral (swallowed) programs

Captured compounded oral programs. These are not Rybelsus and do not inherit PIONEER/OASIS evidence.

Terminology and formulation distinctions

The words providers use here are not interchangeable, and treating them as synonyms is the most common mistake a shopper makes. An orally disintegrating tablet (ODT) dissolves on the tongue and is largely swallowed, so most absorption occurs through the gut. A sublingual product is placed under the tongue with the intent that the drug absorb through the oral mucosa directly into the bloodstream, bypassing the gut. A buccal product sits between cheek and gum with a similar mucosal-absorption intent. A troche is a medicated lozenge that dissolves slowly in the mouth. A swallowed oral tablet or capsule goes through the digestive tract like any pill. These are genuinely different delivery routes with genuinely different absorption behavior, and a peptide like semaglutide behaves very differently depending on which one it's in. This page keeps them separate and never merges them into a single ranking.

Route of administration and why it matters for peptides

Semaglutide and tirzepatide are large peptide molecules, and getting a peptide into the bloodstream through anything other than injection is difficult. Peptides are poorly absorbed across the gut and oral mucosa, and they're vulnerable to degradation by digestive enzymes and stomach acid. This is why the approved injectable products are injected: it's the route with reliable, well-characterized absorption. The moment a compounded product moves the same molecule to an oral, sublingual, or ODT route, the central question becomes how much of the drug actually reaches the bloodstream — and for compounded products, that question is usually unanswered, because the specific formulation hasn't been studied for bioavailability.

FDA-approved oral products for comparison

There is exactly one FDA-approved oral GLP-1 product relevant here: Rybelsus, an oral semaglutide tablet. Its approval is instructive precisely because of how much engineering it required. Rybelsus achieves absorption only through a specific co-formulation with an absorption enhancer called SNAC, must be taken on an empty stomach with a small sip of water, and requires a waiting period before eating or taking other medications — and even then its bioavailability is low and variable, which is why its doses differ from the injectable's. There is no FDA-approved oral tirzepatide at all. The existence of Rybelsus proves the route can work, but only with substantial formulation science behind it — science a compounded oral product generally does not have.

Compounded-product distinction

A compounded oral, ODT, or sublingual GLP-1 product is not Rybelsus and does not share its formulation. It's a pharmacy preparation whose absorption enhancers, if any, and whose actual bioavailability are typically uncharacterized for the specific product dispensed. Two compounded "sublingual semaglutide" products from different pharmacies may absorb completely differently, and neither may have been tested to establish how much drug reaches the blood. This is a different and larger uncertainty than compounded injectables face: with an injectable, the route's absorption is well understood and the open question is formulation quality; with a compounded oral or sublingual product, both the formulation quality and the route's absorption for that specific preparation are open questions.

Formulation-specific evidence

The honest summary of the evidence is that, for compounded oral, ODT, and sublingual GLP-1 products, formulation-specific efficacy and bioavailability data are generally absent. The pivotal weight-loss trials used injections. Rybelsus's trials (the PIONEER and OASIS programs) used Rybelsus's specific SNAC formulation, not any compounded product. No body of randomized evidence establishes that a given compounded sublingual or ODT semaglutide achieves blood levels, weight loss, or safety comparable to any approved product. Real-world and provider-reported claims exist, but they don't substitute for bioavailability and efficacy data on the specific formulation, and they typically don't measure blood levels at all. A consumer should treat a compounded oral or sublingual GLP-1 as a product whose fundamental question — does enough drug get in to work — is unanswered for the specific thing they'd be buying.

Absorption and bioavailability limitations

Bioavailability is the fraction of an administered dose that reaches the bloodstream, and for oral and mucosal peptide delivery it tends to be both low and highly variable. Variability is the underappreciated problem: even if some drug absorbs, an inconsistent fraction from dose to dose means unpredictable exposure, which for a weight-management medication translates to unpredictable effect. Sublingual claims deserve particular scrutiny, because true sublingual absorption of a large peptide through the oral mucosa is hard to achieve, and a product marketed as "sublingual" may in practice be mostly swallowed and degraded. Without formulation-specific pharmacokinetic data — which compounded products generally lack — there is no way to know what a given product actually delivers.

Why injectable evidence doesn't transfer

The strongest evidence in this drug class — the weight-loss percentages from STEP and SURMOUNT — comes from injections, and it does not transfer to oral or sublingual routes. Those trials measured what happens when a known, reliably absorbed dose reaches the bloodstream by injection. An oral or sublingual product's effect depends entirely on how much drug its particular formulation gets into the blood, which is the very thing that's uncharacterized. Marketing that places injectable weight-loss figures beside a compounded oral or sublingual product invites an inference the evidence can't support. Injectable evidence establishes what the molecule does at a given blood level; it says nothing about whether a compounded tablet or sublingual drop achieves that level.

Pricing

ODT (orally disintegrating tablet) programs

Captured ODT programs. ODT, sublingual, and swallowed-oral products are different formulations and are never merged into one ranking.

Sublingual programs

Captured sublingual programs. Sublingual absorption is formulation-specific and uncharacterized for compounded products.

Oral (swallowed) programs

Captured compounded oral programs. These are not Rybelsus and do not inherit PIONEER/OASIS evidence.

Pharmacy and formulation transparency

Because absorption is the central uncertainty, the formulation details matter more for oral and sublingual products than for injectables — yet they're often the least disclosed. Before considering a compounded oral or sublingual GLP-1, the questions to press are: which pharmacy compounds it, what the active-ingredient strength and form are, whether the formulation includes any absorption enhancer and which one, and whether the pharmacy has any bioavailability data for the specific product. Vague answers are themselves a finding. Verify the dispensing pharmacy with the four-step workflow, and treat any claim of injectable-equivalent results without formulation-specific data as unsupported.

Safety and uncertainty

The safety profile of a compounded oral or sublingual GLP-1 is uncertain in a specific way: it's not that these routes are known to be dangerous, but that their absorption — and therefore the actual dose reaching the bloodstream — is unpredictable, which complicates both efficacy and dose safety. Unpredictable exposure can mean too little drug to help or, in principle, more than expected. The general GLP-1 side-effect profile (nausea, gastrointestinal effects, and the serious warnings that apply to the class) still applies to whatever drug is absorbed. And the compounding-quality uncertainties that affect all compounded products apply here too. As always, whether any of these products is appropriate for you is a clinical decision for a licensed prescriber, and this page offers no dosing guidance.

Research gaps

The open questions are foundational: there's little to no published bioavailability data for most compounded oral, ODT, and sublingual GLP-1 formulations; no randomized efficacy trials of compounded oral or sublingual products for weight management; and no standardization across pharmacies, so findings about one product wouldn't transfer to another. Until formulation-specific pharmacokinetic and outcome data exist, these products' core claim — that they deliver the drug's benefits by a non-injection route — remains unverified. Our research library tracks the approved-product oral evidence (Rybelsus's PIONEER and OASIS programs) and will add compounded-formulation studies as they appear, clearly separated.

Frequently asked questions

Do compounded oral or sublingual GLP-1 products work as well as injections?

There's no evidence establishing that they do. The weight-loss results come from injections, and they don't transfer to oral or sublingual routes, whose absorption for compounded products is generally uncharacterized. The core question — how much drug actually reaches the bloodstream — is usually unanswered for the specific compounded product. Treat injectable-equivalent claims without formulation-specific data as unsupported.

Is compounded oral semaglutide the same as Rybelsus?

No. Rybelsus is an FDA-approved tablet with a specific absorption-enhancer formulation and strict dosing conditions, validated in dedicated trials. A compounded oral semaglutide is a different, unstudied preparation that doesn't share Rybelsus's formulation and doesn't inherit its evidence. The two are not interchangeable, and Rybelsus's approval says nothing about any compounded product's absorption or effect.

Is sublingual semaglutide actually absorbed under the tongue?

That's the open question, and it deserves scrutiny. True sublingual absorption of a large peptide through the oral mucosa is difficult, and a product marketed as "sublingual" may in practice be mostly swallowed and degraded. Without formulation-specific pharmacokinetic data — which compounded products generally lack — there's no way to confirm how much drug the product delivers or by which route.

Why would someone choose an oral or sublingual product over an injection?

Usually needle avoidance or convenience. Those are real preferences, but they have to be weighed against the central uncertainty that these routes may deliver an unpredictable and possibly inadequate fraction of the dose. A more comfortable product that doesn't reliably get the drug into your bloodstream isn't a better product. This is a trade-off to discuss with a prescriber, not to resolve from a marketing page.

Are ODT, sublingual, and oral the same thing?

No, and treating them as synonyms is a common and consequential mistake. An ODT dissolves and is mostly swallowed (gut absorption), a sublingual product is meant to absorb under the tongue (mucosal absorption), and an oral tablet is swallowed like any pill. They're different routes with different absorption behavior, and a claim about one doesn't apply to another. This page keeps them separate for that reason.

Is compounded ODT or sublingual GLP-1 FDA approved?

No. No compounded GLP-1 product is FDA approved, in any formulation. The only FDA-approved oral GLP-1 is Rybelsus, which is not a compounded product. Compounded oral, ODT, and sublingual products are prepared without premarket FDA review of absorption, effectiveness, or safety for the specific formulation dispensed.